前列腺癌:KOL (關鍵意見領袖) 分析
Prostate Cancer: KOL Insight
本報告提供前列腺癌的已上市藥物及正在開發的藥物的相關調查，前列腺癌的治療方法的變化，治療的選項，STAMPEDE及CHAARTED實驗與其影響，聯合治療疑慮，未滿足需求等相關資料，美國及歐洲的12名關鍵意見領袖 (KOL) 的各種見解彙整。
The last decade has seen significant change in how prostate cancer is treated. Innovation and lifecycle management have each played a role in shaping today's treatment paradigm. But how will results from landmark studies such as STAMPEDE and CHAARTED impact current treatment decisions? And which products will emerge victorious in the battle for market share?
Prostate Cancer: KOL Insight looks at the future of prostate cancer therapy and provides insight from 12 leading North American and European KOLs. How will marketed and late-stage pipeline drugs continue to be used?
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.